Full-Time

Director – US Marketing

Nf1-PN

Posted on 10/31/2025

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$165k - $230k/yr

+ Discretionary Annual Bonus

Boston, MA, USA

Hybrid

On-site required 2 days/week (Tue and Wed) or more per business needs.

Category
Growth & Marketing (1)
Required Skills
Risk Management
Marketing
Requirements
  • Bachelor's degree (business or related disciplines)
  • 9+ years of relevant pharmaceutical and/or biotechnology commercial experience
  • 3+ years people leadership experience
  • Successful track record in understanding the U.S. regulatory environment and navigating the MLR review process
  • Microsoft Office
  • Veeva Promo Mats
  • Brand planning
  • Launch and tactical planning
  • Results-oriented, exhibits leadership skills, and ability to influence and motivate without authority
  • Proven ability to lead and collaborate with cross-functional teams
  • Team player and strong track record of collaboration
  • High ethical standards and personal integrity
  • Strong sense of urgency and ability to organize, prioritize, activate and execute
  • Team player and strong track record of collaboration, particularly across Marketing and Sales teams
Responsibilities
  • Lead annual HCP strategic planning and develop tactical plans for key market-shaping and branded activities, determine budgets, timelines and metrics for program success to ensure brand launch success in collaboration with cross-functional and vendor partners
  • Own the tactical development, execution and measurement of personal and non-personal promotion for HCP and nurse audiences
  • Own relationship with HCP Media/Digital Agency of Record and oversee strategy and execution, including targeting strategy, media asset development, and media KPI reporting and optimization
  • Evolve data/insights-driven omnichannel strategy and planning, including building out HCP journeys, developing personalized story flows for HCP engagement, executing omnichannel-driven engagement, and measuring performance
  • Work cross-functionally to develop a detailed KTL engagement strategy and plan; lead marketing-driven programs involving partnership with KTLs
  • Oversee strategic direction for HCP congresses, including identification and execution of event sponsorships, symposiums, and exhibit and conference material development
  • Support the development and execution of speaker bureau and other peer to peer educational programs directed at HCPs at congresses, lunch and learns, dinner programs, and digital execution; lead creation of all content associated with peer-to-peer programs including speaker decks and invitations
  • Work with Marketing Operations to manage HCP & Nurse resource printing and fulfillment in the portal (details, inventory, downloads)
  • Work with internal and external partners to define success metrics and analyze performance of marketing programs on an ongoing basis, ensuring plans are optimized as needed to improve impact, and develop recommendations for future plans
  • Partner with sales training and sales leadership to optimize the development and utilization of personal promotional materials and ensure materials are appropriately rolled out to field teams at both new hire and POA meetings
  • Deliver field force training and communications as needed, ensuring they have the knowledge and resources to effectively represent brand positioning and messages
  • Engage with the global marketing team to ensure alignment and appropriate US pull-through; lead integration of global HCP campaign into US materials
  • Collaborate with broader rare tumor marketing team to ensure strategic alignment and execution across the SpringWorks portfolio
  • Ensure legal/regulatory compliance and medical accuracy of all marketing tactics
  • Manage agency partner relationships, workflows, and related expense budgets
  • Manage owned budget line items on an ongoing basis and ensure spend and gating are reconciled on time & accurately
  • Participate in regular field rides and share appropriate insights back with team
  • Ability to independently and proactively identify strategic opportunities, build plans and execute against them
  • Attend and/or participate at conventions, conferences, and tradeshows, preparing engaging displays and collateral as needed, and providing post-event reports and analysis
  • Ability to lead projects and make key decisions without day-to-day oversight
  • Ability to effectively prioritize projects & initiatives based on aligned business objectives
  • Ability to think and act strategically, drive performance, foster relationships and build internal and external alignment
  • Strong communications skills and track record of effective and influential presentations to external and internal stakeholders
  • Initiative, creativity, and ability to work effectively in complex, rapidly changing environment
  • Possess strong business insight skills, as role is responsible for managing budgets, timelines, processes and procedures
  • Proficient in digital marketing, omnichannel, and media tactics directed towards HCPs
  • Proven project and vendor management skills including budget management, planning, prioritization, objective setting, and logistics execution
  • Adept in expense budget planning, tracking, and ROI measurement
Desired Qualifications
  • MBA or other advanced degree preferred
  • 4+ years in a product manager role strongly desired
  • Sales experience preferred
  • Oncology experience preferred
  • Understanding of US Oncology landscape including Community Oncology and Academic Oncology dynamics, GPOs, Payer landscape, Specialty Pharmacy stakeholders preferred
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck KGaA acquired SpringWorks for $3.9B on July 1, 2025.
  • Acquisition adds immediate revenue from Ogsiveo and Gomekli.
  • CHMP positive opinion for mirdametinib expands EU access.

What critics are saying

  • Merck KGaA drops two SpringWorks pipeline assets post-acquisition.
  • European Commission rejects mirdametinib approval due to pediatric data.
  • Pimicotinib outperforms Ogsiveo in desmoid tumor trials.

What makes SpringWorks Therapeutics unique

  • Ogsiveo is first FDA-approved therapy for desmoid tumors.
  • Gomekli is first approved therapy for NF1-PN in adults and children.
  • Precision medicines target rare cancers via genetic profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

5%
AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb.com
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.

IT Juzi
Apr 28th, 2025
Merck Acquires SpringWorks for $3.9B

German Merck Group has announced a $3.9 billion acquisition agreement with U.S. biopharmaceutical company SpringWorks Therapeutics. This acquisition aims to enhance Merck's cancer drug business. SpringWorks Therapeutics, a biopharmaceutical developer, has obtained four potential new drugs in clinical stages from Pfizer.

INACTIVE